首页> 外文OA文献 >BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

【2h】

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

机译：BMI1抑制剂PTC596与MCL1抑制剂S63845或MEK抑制剂TRAMETINIB组合治疗急性白血病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Katja Seipel; Basil Kopp; Ulrike Bacher; Thomas Pabst;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study [J] . Ragon Brittany Knick, Odenike Olatoyosi, Baer Maria R., Clinical lymphoma, myeloma & leukemia . 2019,第7期

机译：口服梅克1/2抑制剂Trametinib与AKT抑制剂GSK2141795与RAS突变的急性髓性白血病患者组合：II期研究
2. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia [J] . S Degryse, C E de Bock, S Demeyer, Leukemia . 2018,第3期

机译：突变JAK3磷酸化蛋白质组学分析预测JAK3抑制剂与MEK / BCL2抑制剂之间的协同作用，可治疗T细胞急性淋巴细胞白血病
3. Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia [J] . S. Degryse, C. E. de Bock, S. Demeyer, Leukemia . 2018,第12期

机译：更正：突变的JAK3磷酸化蛋白质组学分析预测JAK3抑制剂和MEK / BCL2抑制剂之间的协同作用，可治疗T细胞急性淋巴细胞白血病
4. Development of Combined PK/PD Studies of RAF/MEK/mTOR Inhibitors for the Treatment of Pediatric Low-Grade Astrocytomas by MALDI Mass Spectrometry Imaging [C] . David Calligaris, Xiaohui Liu, Daniel Feldman, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2013

机译：RAF / MEK / MTOR抑制剂组合PK / PD研究的研制治疗MALDI质谱成像治疗儿科低级星形细胞瘤
5. Comparison of FLT3 Inhibitors with the Standard Treatment for FLT3-ITD Mutated Acute Myeloid Leukemia [D] . Argetsinger, Stephanie. 2018

机译：FLT3抑制剂对FLT3-ITD突变急性髓性白血病标准治疗的比较
6. BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia [O] . Katja Seipel, Basil Kopp, Ulrike Bacher, 2021

机译：BMI1抑制剂PTC596与MCL1抑制剂S63845或MEK抑制剂TRAMETINIB组合治疗急性白血病
7. Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia [O] . S. Degryse, C. E. de Bock, S. Demeyer, 2018

机译：校正：突变体JAK3磷蛋白质分析预测JAK3抑制剂和MEK / BCL2抑制剂之间的协同作用，用于治疗T细胞急性淋巴细胞白血病

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

著录项

引文网络

相似文献

相关主题

期刊订阅